The drug abiraterone can add four months to the lives of men with advanced prostate cancer if given before chemotherapy, evidence suggests. 

Currently given to NHS patients after chemotherapy, the drugs regulator had rejected expanding its use, partly over questions about survival. 

Charities say the medicine should now be given to all patients who need it. 

The Institute of Cancer Research said the drug might be more beneficial for patients with very aggressive cancer.

For more details, go to: http://www.bbc.com/news/health-31146920